

# Human Herpesvirus 8 Seroprevalence, China

Tiejun Zhang, Xiaodan Shao, Yue Chen,  
Tao Zhang, Veenu Minhas, Charles Wood,  
and Na He

To summarize the seroprevalence of human herpesvirus 8 (HHV-8) in mainland China, we conducted a systematic review and meta-analysis based on available literature. Data show that differences in HHV-8 prevalence vary considerably among different ethnic groups and geographic regions. Blood-borne transmission could be a potential route for HHV-8 infection in China.

**H**uman herpesvirus 8 (HHV-8) is the infectious etiology agent associated with Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Worldwide seroprevalence of HHV-8 varies: generally low to moderate for populations in Western countries and Asia (1–4) but as high as 50% for the general population in sub-Saharan Africa and higher for HIV-positive populations (5–7). The transmission modes of HHV-8 may also differ in different geographic areas and subpopulations; sexual and nonsexual transmission have been described (8–10). Blood-borne transmission may exist, especially among intravenous drug users (IVDUs) and blood recipients (11).

The Ministry of Health of China, the United Nations Program on HIV/AIDS, and the World Health Organization estimate that ≈320,000 HIV/AIDS cases have been reported in China (12). However, the epidemiologic characteristics of HHV-8 infection, a severe HIV/AIDS opportunistic infection, have not been well described for China. Therefore, we conducted a systematic review and meta-analysis on the basis of available data for HHV-8 epidemiology from mainland China to have a better understanding of the prevalence, variation, and factors associated with its transmission.

Author affiliations: Fudan University, Shanghai, People's Republic of China (T. Zhang, X. Shao, Tao Zhang, V. Minhas, C. Wood, N. He); University of Nebraska-Lincoln, Lincoln, Nebraska, USA (T. Zhang, V. Minhas, C. Wood); and University of Ottawa, Ottawa, Ontario, Canada (Y. Chen)

DOI: <http://dx.doi.org/10.3201/eid1801.102070>

## The Study

A comprehensive literature search of published studies indexed in global and databases in China during 1995–2010 was conducted. Initially, 125 reports published in English and 223 in Chinese concerning the seroprevalence in mainland China were identified. Among them, 85 articles published in England and 178 articles published in China were excluded after title and abstract screening. After reading the full text, we excluded another 33 English and 26 Chinese articles. Finally, 26 publications were included in this systematic review and have been summarized in online Technical Appendix Table 1 ([wwwnc.cdc.gov/EID/pdfs/10-2070-Techapp.pdf](http://wwwnc.cdc.gov/EID/pdfs/10-2070-Techapp.pdf)). These studies were cross-sectional and were conducted in 8 of the 34 provinces. A substantial number (35.5%) of these studies were conducted in the Xinjiang Uygur Autonomous Region. Most samples tested were serum or plasma with few exceptions (1 whole blood, 1 peripheral blood mononuclear cells); sample sizes ranged from 37 to 4,461 (median 242, interquartile range 199–520). Overall, 18,547 participants were involved in the present analysis, and among them 15,913 were from the general population, 1,970 were immunocompromised patients, and 664 were IVDUs. Laboratory methods for all included studies were reported (19 detected HHV-8 by ELISA, 3 by PCR, and 4 by immunofluorescent assay).

The prevalence of HHV-8 pooled from reviewed studies was 11.3% (95% CI 7.2–15.5) for the general population, 22.2% (95% CI 12.7–31.8) for immunocompromised patients, and 31.2% (95% CI 27.7–34.7) for IVDUs. The prevalence among the general population was found to be the lowest in Guangdong Province and the highest in Xinjiang Province. A similar regional variation was found for immunocompromised persons. Among IVDUs, the prevalence was 34.3% (95% CI 28.3–40.3) in Zhejiang and 29.6% (95% CI 25.3–33.9) in Xinjiang Uygur Autonomous Region (online Technical Appendix Table 2; Figure).

Five studies, including 4,637 persons of Han ethnicity and 4,011 persons of ethnic minorities (2,040 Uygur, 1,169 Kazak, 200 Khalkas, 173 Hue, and 429 other) conducted in the Xinjiang Uygur Autonomous Region were analyzed for association of ethnicity with HHV-8 prevalence (online Technical Appendix Figure, panel A). The risk was significantly lower for the Han group than for other ethnic groups (odds ratio [OR] = 0.59, 95% CI 0.55–0.76). For the Han group, the pooled prevalence of HHV-8 in Xinjiang Uygur Autonomous Region was significantly higher when compared with that for other regions, 14.4% (95% CI 9.0–19.8) versus 6.4% (95% CI 4.1–8.6). Ten combined studies, with 5,716 male and 4,708 female participants, respectively, were included in meta-analysis of association between sex and HHV-8 infection (online Technical Appendix Figure, panel B).

There was no significant difference between the sexes: pooled OR 0.94 (95% CI 0.84–1.04).

Seven studies, with 863 HIV-positive patients and 3,438 negative controls, were included in the analysis. All studies yielded a significant difference in HHV-8 infection between HIV-positive and HIV-negative participants; ORs for individual studies ranged from 1.50 to 4.27, and the pooled OR was 2.97 (95% CI 2.22–3.97) (online Technical Appendix Figure, panel C). However, a significant publication bias was detected (Egger test  $p = 0.013$ ; Begg test  $p = 0.016$ ). A visual inspection of the funnel plot suggested that some large or small studies with negative or null results were not published (data not shown).

Few studies were designed to address the issue of possible transmission routes among the population of China. Six studies had information on possible blood transmission. Two blood transfusion studies and 4 studies of IVDUs included 837 persons who reported having been exposed to blood contact i.e., needle sharing and 1,397 who were never exposed (online Technical Appendix Figure, panel D). Substantial heterogeneity ( $I^2 87\%$ ,  $p < 0.001$ , by test for heterogeneity) was detected among those studies; therefore, a random-effects model was used to estimate the OR. No publication bias was detected (Begg test  $p = 0.707$ ; Egger test  $p = 0.363$ ). OR showed a marginal association of HHV-8 prevalence with blood transfusion (OR 2.01, 95% CI 0.89–4.56) for possible blood transmission.

## Conclusions

This systematic review indicated that HHV-8 prevalence in China varies in different regions. Pooling of data from 26 studies provided us with a large sample size, which is one of the strengths of the study. Also, we included studies that were published in the Chinese language and were not accessible to the international community. The results of this meta-analysis show that HHV-8 prevalence was higher in the Xinjiang Uygur Autonomous Region than other areas in general and among high-risk populations. Historically, Xinjiang Uygur Autonomous Region has been regarded as an area in which Kaposi sarcoma is endemic (13). Notably, geographic variations of HHV-8 infection within China are not well known and need to be investigated as well.

It has been well documented that HHV-8 prevalence is higher among HIV-infected persons (14,15). In mainland China, we found a 3-fold increase in HHV-8 infection among persons with HIV compared with HIV-noninfected persons. Given the rapid increase of HIV/AIDS cases in China, HHV-8 could become a severe public health issue in the future.

According to data from the Xinjiang Uygur Autonomous Region, minority groups were at higher risk for HHV-8 infection than the Han ethnic group. Although there was




Figure. Regional distribution of pooled human herpesvirus 8 (HHV-8) prevalence in A) the general population and B) immunocompromised patients, China.

evidence for considerable heterogeneity among the studies, the association between ethnicity and HHV-8 risk showed that minorities were at higher risk for HHV-8 infection when compared with the Han ethnic group. The reasons behind this association are not well elucidated. Because all of the comparisons of HHV-8 difference between minority groups and the Han ethnic group are from the Xinjiang Uygur Autonomous Region, epidemiologic confirmation of this observation would require data from other regions, which is currently unavailable. Our analysis showed a marginally significant association between blood contact and HHV-8 infection; heterogeneity among studies was substantial. These data indicate that blood-borne transmission could occur among the Chinese population, a finding that is consistent with previous reports from other countries (11).

This study has some limitations. The studies included in this meta-analysis were not evenly distributed throughout China because information was not available from all the regions. Also, all of the studies might have used different methods for HHV-8 detection because of the lack of a standard assay; prevalence estimates may have been underestimated.

In summary, this meta-analysis clearly shows that the distribution of HHV-8 seroprevalence varies in China. The available information is still too limited to fully understand HHV-8 prevalence and the risk factors associated with transmission. Further studies are urgently needed to explore the epidemiology of HHV-8 infection in different subpopulations in China.

This study was supported by the National Institutes of Health (PHS grant RO1 CA75903; Fogarty International Training Grant D43 TW01492 and T32 AI060547) and a National Center for Research Resources Centers of Biomedical Research Excellence grant (grant P30 RR031151) to C.W. The study was also funded, in part, by the Fundamental Research Funds for the Central Universities (10FX058) and Chinese National Natural Science Foundation (81072345).


Dr Tiejun Zhang is a postdoctorate research fellow at the University of Nebraska-Lincoln and a lecturer at the School of Public Health, Fudan University. His research focuses on HHV-8 and HIV epidemiology in China.

## References

- Hoffman LJ, Bunker CH, Pellett PE, Trump DL, Patrick AL, Dollard SC, et al. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. *J Infect Dis*. 2004;189:15–20. doi:10.1086/380568
- Laney AS, Peters JS, Manzi SM, Kingsley LA, Chang Y, Moore PS. Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. *J Clin Microbiol*. 2006;44:3734–41. doi:10.1128/JCM.00191-06
- Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. *Transfusion*. 2003;43:1260–8. doi:10.1046/j.1537-2995.2003.00490.x
- Huang LM, Huang SY, Chen MY, Chao MF, Lu CY, Tien HF, et al. Geographical differences in human herpesvirus 8 seroepidemiology: a survey of 1,201 individuals in Asia. *J Med Virol*. 2000;60:290–3. doi:10.1002/(SICI)1096-9071(200003)60:3<290::AID-JMV7>3.0.CO;2-G
- Baeten JM, Chohan BH, Lavreys L, Rakwar JP, Ashley R, Richardson BA, et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. *AIDS*. 2002;16:2073–8. doi:10.1097/00002030-200210180-00013
- Engels EA, Sinclair MD, Biggar RJ, Whitby D, Ebbesen P, Goedert JJ, et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. *Int J Cancer*. 2000;88:1003–8. doi:10.1002/1097-0215(20001215)88:6<1003::AID-IJC26>3.0.CO;2-9
- Rezza G, Tchamgomena OB, Andreoni M, Bugarini R, Toma L, Bakary DK, et al. Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. *Sex Transm Dis*. 2000;27:159–64. doi:10.1097/00007435-200003000-00008
- Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neillands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. *J Infect Dis*. 2009;200:430–8. doi:10.1086/600103
- Mbulaiteye S, Marshall V, Bagni RK, Wang CD, Mbisa G, Bakaki PM, et al. Molecular evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host. *J Infect Dis*. 2006;193:1250–7. doi:10.1086/503052
- Dukers NH, Renwick N, Prins M, Geskus RB, Schulz TF, Weverling GJ, et al. Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. *Am J Epidemiol*. 2000;151:213–24.
- Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, et al. Transmission of human herpesvirus 8 by blood transfusion. *N Engl J Med*. 2006;355:1331–8. doi:10.1056/NEJMoa055009
- Ministry of Health of China. Joint United Nations Programme on HIV/AIDS, World Health Organization. The Estimation of HIV/AIDS in China in 2009. Beijing: Ministry of Health; 2010. p. 10.
- Dilnur P, Katano H, Wang ZH, Osakabe Y, Kudo M, Sata T, et al. Classic type of Kaposi's sarcoma and human herpesvirus 8 infection in Xinjiang, China. *Pathol Int*. 2001;51:845–52. doi:10.1046/j.1440-1827.2001.01293.x
- Parisi SG, Sarmati L, Pappagallo M, Mazzi R, Carolo G, Farchi F, et al. Prevalence trend and correlates of HHV-8 infection in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2002;29:295–9.
- Chakraborty R, Rees G, Bourboullia D, Cross AM, Dixon JR, D'Agostino A, et al. Viral coinfections among African children infected with human immunodeficiency virus type 1. *Clin Infect Dis*. 2003;36:922–4. doi:10.1086/368207

Address for correspondence: Tiejun Zhang or Na He, Department of Epidemiology, School of Public Health, Fudan University, 138# Yi Xue Yuan RD, Shanghai 200032, China; email: tjzhangsh@gmail.com

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.



# Human Herpesvirus 8 Seroprevalence, China

## Technical Appendix

Technical Appendix Table 1. Summary of data from literature on HHV8 prevalence, China\*

Author, year	District	Design	Sample	Detection method	Sample collection year(s)	Target population	Sample size	HHV-8 prevalence (95% CI)
Qi et al., 2005	Shandong	Cross-sectional	Serum	ELISA	2003/2004	General population	303	6.3 (3.6–9.0)
Qi et al., 2006	Shandong	Cross-sectional	Serum	ELISA	2003/2004	General population	520	6.0 (4.0–8.0)
Qi et al., 2007	Shandong	Cross-sectional	Serum	ELISA	NA	General population	230	5.7 (2.7–8.7)
	Shandong	Cross-sectional	Serum	ELISA	NA	Immunocompromised persons†	86	16.3 (8.5–24.1)
Li, et al, 2008	Shandong	Cross-sectional	Plasma	ELISA	2005/2006	General population	460	5.7 (3.6–7.8)
Wang et al., 2000	Zhejiang	Cross-sectional	Serum/plasma	ELISA	1998/1999	Drug user	242	34.3 (28.3–40.3)
Wang et al., 2001	Zhejiang	Cross-sectional	Plasma	ELISA	1998/1999	General population	241	16.2 (11.5–20.9)
Zhu et al., 2008	Zhejiang	Cross-sectional	Plasma	ELISA	NA	Immunocompromised persons	214	36.4 (30.0–42.8)
			Plasma	ELISA	NA	General population	122	13.0 (7.0–19.0)
Fu et al., 2006‡	Guangdong	Cross-sectional	Whole blood	PCR	NA	General population	239	0.8 (0.0–1.9)
Fu et al., 2006‡	Guangdong	Cross-sectional	Plasma	ELISA	2004/2005	General population	3,135	0.2 (0.0–0.4)
Guan et al., 2008	Guangdong	Cross-sectional	Serum	ELISA	NA	Immunocompromised persons	167	0.6 (0.0–1.8)
Fu et al., 2009‡	Hubei	Cross-sectional	Serum	ELISA	2004/2005	General population	560	6.8 (4.7–8.9)
Fang et al., 2006	Hubei	Cross-sectional	Serum	ELISA	2004/2005	General population	560	5.2 (3.4–7.0)
Wang et al., 2002	Dongbei§	Cross-sectional	PMBC	PCR	NA	General population	230	7.8 (4.3–11.3)
Zhang et al., 2010	Shanxi	Cross-sectional	Plasma	IFA	2004/2005	General population	315	4.8 (2.4–7.2)
			Plasma	IFA	2004/2005	Immunocompromised persons	305	15.4 (11.3–19.5)
Du et al., 2000	Xinjiang	Cross-sectional	Serum	IFA	NA	General population	1,071	24.5 (21.9–27.1)
Sun, et al., 2002	Xinjiang	Cross-sectional	Serum	ELISA	1998–2000	Immunocompromised persons	56	28.5 (16.7–40.3)
Sun et al., 2003	Xinjiang	Cross-sectional	Serum	IFA	2000	General population	406	15.5 (12.0–19.0)
Qing et al., 2005	Xinjiang	Cross-sectional	Serum	PCR	2002/2003	General population	68	22.1 (12.2–32.0)
Wu et al., 2005	Xinjiang	Cross-sectional	Serum	IFA	NA	General population	204	30.4 (24.1–36.7)
He et al., 2007‡	Xinjiang	Cross-sectional	Serum	ELISA	NA	Immunocompromised persons	155	26.5 (19.6–33.4)
He et al., 2007‡	Xinjiang	Cross-sectional	Serum	ELISA	2004	Immunocompromised persons	482	25.3 (21.4–29.2)
Fu et al., 2009‡	Xinjiang	Cross-sectional	Serum	ELISA	2007	General population	2,228	19.2 (17.6–20.8)

Author, year	District	Design	Sample	Detection method	Sample collection year(s)	Target population	Sample size	HHV-8 prevalence (95% CI)
			Serum	ELISA	2007	Immunocompromised persons	37	43.2 (27.2–59.2)
	Hubei	Cross-sectional	Serum	ELISA	2007	General population	560	9.5 (7.1–11.9)
Yang et al., 2009	Xinjiang	Cross-sectional	Serum	ELISA	2006	Immunocompromised persons	468	14.3 (11.1–17.5)
Wang, et al., 2010	Xinjiang	Cross-sectional	Serum	ELISA	NA	General population	4,461	20.4 (19.2–21.6)
Yang et al., 2010‡	Xinjiang	Cross-sectional	Serum	ELISA	2006	Drug user	223	28.7 (22.8–34.6)
Yang et al., 2010‡	Xinjiang	Cross-sectional	Serum	ELISA	2006	Drug user	199	30.6 (24.2–37.0)

\*HHV8, human herpesvirus 8; NA, not applicable.

†Immunocompromised persons include patients with tumors, organ transplant recipients, HIV-positive patients, and other patients with immunosuppressed-related conditions.

‡From same first author in 1 year.





§Dongbei includes the provinces of Heilongjiang, Jilin, and Liaoning.

Technical Appendix Table 2. Distribution of HHV-8 prevalence among different subpopulations in mainland China\*

Population type and province	Author, year	Sample size	HHV-8 prevalence (95% CI)	Pooled prevalence by region (95% CI)
General population				
Shandong	Qi et al., 2005	303	6.3 (3.6–9.0)	5.9 (4.7–7.1)
	Qi et al., 2006	520	6.0 (4.0–8.0)	
	Qi et al., 2007	230	5.7 (2.7–8.7)	
	Li et al., 2008	460	5.7 (3.6–7.8)	
Zhejiang	Wang et al., 2001	241	16.2 (11.5–20.9)	15.0 (11.3–18.7)
	Zhu et al., 2008	122	13.0 (7.0–19.0)	
Guangdong	Fu et al., 2006a	239	0.8 (0.0–1.9)	0.2 (0.0–0.5)
	Fu et al., 2006b	3,135	0.2 (0.0–0.4)	
Hubei	Fu et al., 2009a	560	6.8 (4.7–8.9)	7.1 (4.7–9.4)
	Fu et al., 2009b	560	9.5 (7.1–11.9)	
	Fang et al., 2006	560	5.2 (3.4–7.0)	
Dongbei	Wang et al., 2002	230	7.8 (4.3–11.3)	7.8 (4.3–11.3)
Shanxi	Zhang et al., 2010	315	4.8 (2.4–7.2)	4.8 (2.4–7.2)
Xinjiang	Du et al., 2000	1,071	24.5 (21.9–27.1)	21.2 (18.6–23.9)
	Sun et al., 2003	406	15.5 (12.0–19.0)	
	Qing et al., 2005	68	22.1 (12.2–32.0)	
	Wu et al., 2005	204	30.4 (24.1–36.7)	
	Fu et al., 2009b	2,228	19.2 (17.6–20.8)	
	Wang et al., 2010	4,461	20.4 (19.2–21.6)	
Pooled	NA	NA	11.3 (7.2–15.5)	NA
Immunocompromised persons				
Shandong	Qi et al., 2007	86	16.3 (8.5–24.1)	16.3 (8.5–24.1)
Zhejiang	Zhu et al., 2008	214	36.4 (30.0–42.8)	36.4 (30.0–42.8)
Guangdong	Guan et al., 2008	167	0.6 (0.0–1.8)	0.6 (0.0–1.8)
Shanxi	Zhang et al., 2010	305	15.4 (11.3–19.5)	15.4 (11.3–19.5)
Xinjiang	Sun et al. 2002	56	28.5 (16.7–40.3)	25.6 (17.7–33.4)
	He et al., 2007a	155	26.5 (19.6–33.4)	
	He et al., 2007b	482	25.3 (21.4–29.2)	
	Fu, t al., 2009b	37	43.2 (27.2–59.2)	
	Yang et al., 2009	468	14.3 (11.1–17.5)	
Pooled	NA	NA	22.2 (12.7–31.8)	NA
IV drug users				
Zhejiang	Wang et al., 2000	242	34.3 (28.3–40.3)	34.3 (28.3–40.3)
Xinjiang	Yang et al., 2010a	223	28.7 (22.8–34.6)	29.6 (25.2–33.9)
	Yang et al., 2010b	199	30.6 (24.2–37.0)	
Pooled	NA	NA	31.2 (27.7–34.7)	NA

\*HHV-8, human herpesvirus 8; a, b: From the same first author in one year; IV, intravenous. NA, not applicable.





Technical Appendix Figure. Meta-analysis of herpesvirus 8 (HHV8) prevalence among subgroups in China. A) Comparison of (HHV-8 prevalence between persons of Han ethnicity and of minority ethnicity in Xinjiang, China; B) Comparison of HHV-8 prevalence between male and female study participants in China; C) Comparison of HHV-8 prevalence between persons

with and without HIV infection in China; and D) Comparison of HHV-8 prevalence between blood contact and noncontact subjects.

## **Bibliography**

- Du W, Chen G, et al. Antibody to human herpesvirus type-8 in the general populations of Xinjiang Autonomous Region (A.R.). *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi*. 2000;14:44–6. [PubMed](#)
- Fang Q, Liu J, Bai Z, Kang K, He Z, Hu Z, et al. Seroprevalence of Kaposi's Sarcoma-associated Herpesvirus in the General Population from Hubei Province. *Viol Sin*. 2006;21:97–101.
- Fu B, Li B, Ouyang X, Zeng Y, Xu F, Wang L. Expression of Kaposi s Sarcoma-associated Herpesvirus ORFK8.1 and Its Preliminary Diagnostic Application. *Viol Sin*. 2009;24:202–8. <http://dx.doi.org/10.1007/s12250-009-3029-0>
- Fu B, Sun F, Li B, Yang L, Zeng Y, Sun X, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China. *J Med Virol*. 2009;81:1422–31. [PubMed](#) <http://dx.doi.org/10.1002/jmv.21550>
- Fu Y, Zheng Y, Guang H, Wang C, Jiang C. Seroepidemiology of human herpesvirus 8 among unpaid blood donors in Guangzhou. *Mod Prev Med*. 2006;33:188–9.
- Fu Y, Zhou H, Guang H, Nie Y, Wang C, Jiang C. Detection and sequence analysis of human herpesvirus 8 DNA in unpaid blood donors in Guangzhou. *J Trop Med*. 2006;6:376–8.
- Guan H, Fu Y, Zhou Z, Zhou H. HHV8 antibody test among blood recipients and HBV positive cases. *Chin J Blood Tansfusion*. 2008;21:692–4.
- He F, Wang X, He B, Feng Z, Lu X, Zhang Y, et al. Human herpesvirus 8: serovprevalence and correlates in tumor patients from Xinjiang, China. *J Med Virol*. 2007;79:161–6. [PubMed](#) <http://dx.doi.org/10.1002/jmv.20730>
- He, F., X. Wang, Zhang Y, Hui Y, Lin R, Lu X et al. The epidemiological study on Kaposi's sarcoma asociiated herpasverus among Han patients in Xinjiang. *Journal of Xinjiang Medical University*. 2007;103-6.
- Mei Q, Zhao W, Zhou Y, Luan Y, Bian J, Wang H, et al. Prevalance of human herpesvirus 8(HHV-8)IgG and its associated risk factors in blood donors from Jinan region. [Health Sciences]. *Journal of Shandong University*. 2006;44:328–31.

- Mei Q, Ming ZW, Ping YX, Hui JJ, Bin ZY, Hong W, et al. HHV-8 seroprevalence in blood donors and HIV-positive individuals in Shandong area, China. *J Infect.* 2007;55:89–90. [PubMed](http://dx.doi.org/10.1016/j.jinf.2006.10.046)  
<http://dx.doi.org/10.1016/j.jinf.2006.10.046>
- Mei Q, Ming ZW, Zhang X, Zhou Y, Luan Y, Yu X, et al. Seroepidemiology study on human herpesvirus 8 among health blood donor in Shandong, China. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2005;26:883.
- Peng L, Jian LF. Detection HHV8 infection among health blood donor with ELISA. *Chin J Prim Med Pharm.* 2008;15:512.
- Qin J, Feng L, Tan X, Guo S, Wang X, Zhang W, et al. A case-control study on risk factors of classic Kaposi s sarcoma in Xinjiang. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2005;26:673–5. [PubMed](#)
- Sun H, Chen G, Wang L, Jia E, Zhu L, Du W, et al. Human Herpes virus Type-8 Infection in the Mothers and Their Infants of Wulumuqi and Aletai Region. *Chin J of Perinat Med.* 2003;6:21–3.
- Sun H, Zhou M, Chen G, Du W, Zeng Y. Human herpesvirus 8 IgG antibody test among HIV positive population in Urumuqi. *Chinese J Exp Clin Virol.* 2002;16:195.
- Wang G, Xu H, Zhao Y, Wang Y, Chen H. Detection of Human Herpesvirus 8 in Healthy Blood Donors in Northeast China. *Chin J Derm Venereol.* 2002;16:83–6.
- Wang W, Tong J, Zhao X, Zhang X, Zhang K. Serological study on Kaposi’s sarcoma–associated virus among health blood donor in Zhejiang, China. *Chin J Blood Tansfusion.* 2001;14:46–7.
- Wang W, Zhu B, Zhao X, Zhang X, Shen Y, Gao S. Detection of Kaposi’s sarcoma–associated virus among illegal drug user. *Natl Med J China.* 2000;80:597.
- Wang X, He B, Zhang Z, Liu T, Wang H, Li X, et al. Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors. *Virol J.* 2010;7:62. [PubMed](http://dx.doi.org/10.1186/1743-422X-7-62)  
<http://dx.doi.org/10.1186/1743-422X-7-62>
- Wu W, Pu X, Sun H, Xin Y. Detection of human herpesvirus 8 antibody and DNA among Kaposi’s sarcoma patients. *China J Dermatol.* 2005;38:765.
- Yang P, Guo S, Tan X, Yang L, Fu B, Wang L, et al. Seroepidemiology of Kaposi’s sarcoma–associated herpesvirus in Uigur male drug users from a place in Xinjiang. [Natural Science]. *Journal of Shihezi University.* 2010;28:68–71.
- Yang, P., X. Tan, Guo S, Yang L, Zeng Y, Fu B, et al. Research of Kaposi’s sarcoma–associated herpesvirus in drug users in one city of Xinjiang. *Mod Prev Med.* 2010;37:107–9.



- Yang PR, Guo SX, Tan XH, Yang L. Research on co-infections of HIV and human herpesvirus-8 among the Uygur high-risk groups in a city, Xinjiang. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2009;43:960–4. [PubMed](#)
- Zhang T, He N, Ding Y, Crabtree K, Minhas V, Wood C. Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne infections in central China. *Clin Microbiol Infect*. 2011;17:395–401. [PubMed](#)  
<http://dx.doi.org/10.1111/j.1469-0691.2010.03287.x>
- Zhu B, Chen Y, Xie J, Wu N, Shendu J, Wang Y. Kaposi's sarcoma-associated herpesvirus (KSHV) infection: endemic strains and cladograms from immunodeficient patients in China. *J Clin Virol*. 2008;42:7–12. [PubMed](#) <http://dx.doi.org/10.1016/j.jcv.2007.11.018>